A molecular mechanism that contributes to the progression of Alzheimer’s disease has been discovered by a research team of Heidelberg University. The team, using an Alzheimer’s mouse model, demonstrated that a neurotoxic protein-protein complex is responsible for nerve cells in the brain dying off and the resulting cognitive decline. This finding opens up new perspectives for the development of effective treatments.

Until now, the early phase of drug discovery for the development of new therapeutics has been cost- and time-intensive. Researchers at KIT have developed a platform on which extremely miniaturized nanodroplets with a volume of 200 nanoliters per droplet and containing 300 cells per test can be arranged. This platform enables the researchers to synthesize and test thousands of therapeutic agents on the same chip, saving time and resources.

Researchers at the University of Freiburg, together with partners, have uncovered the mechanism of ultrafast transport by calcium pumps in nerve cells. These pumps, complexes of PMCA2 and neuroplastin proteins, operate at more than 5,000 cycles per second and terminate calcium signals within milliseconds – 100 times faster than previously known. They play a crucial role in rapid information processing in the brain.

Svenja Brodt uses MRI brain scans to investigate how impressions become memories. A better understanding of how long-term memories are formed could help Alzheimer's patients cope with their daily lives. Impaired memory formation could be compensated for by targeted repetition.

Every brain tumor is made up of cells in successive stages of activation. Researchers have now analyzed the individual structure of these activation pyramids in malignant brain tumors. In doing so, they discovered a signaling protein that slows down the transition from a dormant to an activated state by epigenetically reprogramming the cells. The hope is that this will permanently freeze cancer cells in a dormant state and thus halt tumor growth.